PCV71 COST-EFFECTIVENESS OF EZETIMIBE/SIMVASTATIN VERSUS SIMVASTATIN- WILL THE INCREASED RISK OF CANCER MAKE EZETIMIBE/SIMVASTATIN AN INAPPROPRIATE TREATMENT CHOICE?

May 1, 2009, 00:00 AM
10.1016/S1098-3015(10)73832-8
https://www.valueinhealthjournal.com/article/S1098-3015(10)73832-8/fulltext
Section Title :
Section Order : 303
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)73832-8&doi=10.1016/S1098-3015(10)73832-8
HEOR Topics :
Tags :
Regions :